Are CYTK insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies CYTK leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Stock Ratings / Health Care / CYTK / insiders

CORT (63) ARWR (58) TGTX (63) PTGX (65) ⌘ Pro Terminal →

Cytokinetics Incorporated (CYTK) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

Q: Where is CYTK trading relative to its 50-day, 200-day, and 52-week technical levels?

CYTK last traded at $62.03 (-1.52% on volume of 1,561,104 shares), positioning the stock -6.96% below its 50-day simple moving average ($66.67) and -11.49% below its 200-day simple moving average ($70.08). Across its 52-week range of $58.05 to $88.31, CYTK sits at the 13.2% percentile with a 14-day RSI of 46.0 (NEUTRAL RANGE) and an implied next-earnings move of ±6.5% ($58.00 to $66.06).

$62.03 -1.52% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $61.74

Cytokinetics Incorporated (CYTK) carries a Roarable Rating of E (Strong Sell) with 28/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $8.76B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CYTK Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CYTK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Cytokinetics Incorporated (NASDAQ: CYTK) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $62.03 (-1.52% 1D, market cap $8.76B). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, CYTK ranks #852 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CYTK compare to CORT and ARWR in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CYTK carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CORT (Corcept Therapeutics Incorporated) holds a C grade (63/100 RQD, P/E 93.2x, ROIC 4.8%, cap $8.77B) and ARWR (Arrowhead Pharmaceuticals Inc.) posts a D+ grade (58/100 RQD, P/E N/A, ROIC 11.1%, cap $8.46B). Among the 5-stock peer group, TGTX leads on earnings multiple (19.9x) while TGTX leads on capital efficiency (12.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CYTK?

▼

Per CYTK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001061983), Cytokinetics Incorporated generated $88.0M in revenue (+376.6% YoY), -$785.0M in net income, and -$534.8M in free cash flow against $1.42B in total assets and $246.4M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $61.74 (-0.46%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (28/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.0% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-13.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CYTK)Realized 20D OHLCV Swing Band: ±6.5%

Deterministic 5-Pillar Attribution (28/100 Composite)

🔍 WHY CYTK SCORES 28/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (29% of score)

Altman Z-Score 0.45 (DISTRESS RISK (<1.8)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Whale & Options Positioning+7/20 pts (25% of score)

20D Institutional Volume Accumulation (±6.5% realized swing band)

▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)

Capital intensity & 0% operating margin leave 16 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$63.43-0.9% Next Q

Q2 (-2Q)

Grade E$62.86-2.5% Next Q

Q3 (-1Q)

Grade E$61.28+1.2% Next Q

Current

Grade E$62.03-10% Hist 90D α

Trajectory: E (36) → E (28)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CYTK Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CYTK currently carries a cautious 28/100 (E) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($66.67) and Max Pain ($65.13) forces dealer call-delta covering toward $92.73.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CYTK• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CYTK Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 28%NO 72%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

CYTK Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (CYTK)

No recent open-market Form 4 cluster sales or emergency dumps flagged on CYTK. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CYTK)

✓Walkthrough of CYTK's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CYTK // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -6.09%▼ DESCENDING CHANNEL

2026-11-03O $63.31H $63.31L $62.03C $62.03VOL 1.26M

RES: $69.55SUP: $58.22SMA50: $66.67SMA200: $70.08

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CYTK Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CYTK Butterfly Map → + Track CYTK →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

23.9%/yr Implied 5Y Growth

vs. +376.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on CYTK today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CYTK. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CYTK today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CYTK)

Health Care Rank #852 of 1015 ⚔️ CORT vs CYTK Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CYTK vs. CORT, ARWR, TGTX, PTGX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Cytokinetics Incorporated (CYTK) ranks #852 by composite RQD confidence (28/100, grade E) and #122 by equity capitalization ($8.76B). Within this direct 5-issuer industry benchmark cohort, TGTX leads on earnings valuation at 19.9x trailing P/E, while TGTX leads on capital efficiency and profitability with 12.0% ROIC and 83.7% gross margin. PTGX currently holds the highest overall quantitative score in the immediate peer group at 65/100 (C) compared with CYTK at 28/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CYTK ACTIVE Cytokinetics Incorporated	E	28/100	—	—	-35.0%	-1.52%	$8.76B	Benchmark Subject
CORT Corcept Therapeutics Incorporated	C	63/100	93.2x	96.0%	4.8%	-0.81%	$8.77B	/cort-vs-cytk →
ARWR Arrowhead Pharmaceuticals Inc.	D+	58/100	—	—	11.1%	-0.55%	$8.46B	/arwr-vs-cytk →
TGTX TG Therapeutics Inc.	C	63/100	19.9x	83.7%	12.0%	-2.01%	$9.36B	/tgtx-vs-cytk →
PTGX Protagonist Therapeutics Inc.	C	65/100	—	—	-16.7%	-3.78%	$9.37B	/ptgx-vs-cytk →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001061983 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cytokinetics Incorporated (CYTK) reported GAAP revenue of $88.0M (+376.6% vs. FY2024 revenue of $18.5M , and +1069.2% cumulative change since FY2023) , GAAP net income of -$785.0M, operating cash flow of -$510.0M, and free cash flow of -$534.8M (-33.8% YoY). On the balance sheet, CYTK closed FY2025 with $1.42B in total assets against $246.4M in total debt (Altman Z-Score: 0.45, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$88.0M	-$785.0M	-$510.0M	-$534.8M	$1.42B	$246.4M
FY2024 (FY)	2024-12-31	$18.5M	-$589.5M	-$395.9M	-$399.8M	$1.40B	$93.2M
FY2023 (FY)	2023-12-31	$7.5M	-$526.2M	-$414.3M	-$414.7M	$4.84B	$1.13B

3. CYTK Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CYTK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does CYTK compare to CORT and ARWR in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for CYTK?

Where is CYTK trading relative to its 50-day, 200-day, and 52-week technical levels?

CYTK last traded at $62.03 (-1.52% on volume of 1,561,104 shares), positioning the stock -6.96% below its 50-day simple moving average ($66.67) and -11.49% below its 200-day simple moving average ($70.08). Across its 52-week range of $58.05 to $88.31, CYTK sits at the 13.2% percentile with a 14-day RSI of 46.0 (NEUTRAL RANGE) and an implied next-earnings move of ±6.5% ($58.00 to $66.06).

Direct Sub-Reports: CYTK RQD Cockpit CYTK 12M Forecast CYTK Earnings & Move CYTK Dividends & DRIP CYTK Insiders & 13F CYTK Whale Options CYTK Profit Sankey CYTK News & Why

ROARABLE RATING BRIEF • RQD 28/100 (E) ✓ SEC XBRL & RQD VERIFIED

CYTK — Cytokinetics Incorporated: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Cytokinetics Incorporated (CYTK) earns a live Roarable RQD composite score of 28/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $62.03 (-1.52% 1D, market capitalization $8.76B).

Fundamental Cash Engine (3/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of -60.0%, and free cash flow yield of -6.08%.
Whale 13F & Options Flow (7/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (5/20) + Forensic Balance Sheet (8/20): Incorporates a 0.87x equity beta, Altman Z-Score of 0.45, Piotroski F-Score of 5/9, and Debt/Equity of 0.85x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Cytokinetics Incorporated (CYTK) is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry. Reported revenue across the three periods in the SEC financials rose from $7.5M to $18.5M to $88.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Cytokinetics Incorporated (CYTK) reported $88.0M in annual revenue (up from $18.5M in FY2024, +376.6% YoY) and -$785.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($7.5M revenue, -$526.2M net income) through FY2025, CYTK scaled operating cash flow to -$510.0M and free cash flow to -$534.8M, backed by $1.42B in total assets against $246.4M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (E • RQD 28/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -6.08% and institutional whale pillar of 7/20. With Fundamental Cash Engine at 3/20 and Institutional Whale Flow at 7/20, sustained execution supports upside toward the upper end of the $58.05 – $88.31 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 0.87x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are — Investors should note the absence of mapped ripple effects is a gap in the data, not evidence that none exist.

Key Question #1: Can CYTK sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $88.0M and free cash flow of -$534.8M, how will capital allocation balance growth reinvestment against $246.4M in total debt?
Key Question #3: How sensitive is CYTK's 31.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.87x)?

CYTK Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Cytokinetics Incorporated (CYTK) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CYTK Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance Singapore • 23h ago

Cytokinetics, Incorporated (CYTK) stock price, news, quote and history

Yahoo Finance Singapore report covering Cytokinetics Incorporated (CYTK) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

A $1.42M proposed share sale at Cytokinetics (CYTK) draws on Robert Blum’s stock options.

Stock Titan report covering Cytokinetics Incorporated (CYTK) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Cytokinetics (CYTK) Stock Looks Hard To Pin Down Following Strong Heart Drug Updates